 FOSTER CITY, Calif., Sept. 07, 2022 GLOBE NEWSWIRE -- Terns Pharmaceuticals, Inc. Terns or the Company Nasdaq: TERN, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis NASH, today announced that management will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14 at 2:00 p.m. ET. 